The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $15.69

Today's change+0.07 +0.48%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $15.69

Today's change+0.07 +0.48%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Nektar Therapeutics up (U.S.)$0.08

Nektar Therapeutics closed up Friday by (U.S.)$0.08 or 0.48% to (U.S.)$15.69. Over the last five days, shares have gained 2.52% and 38.24% year to date. Shares have outperformed the S&P 500 by 31.39% during the last year.

Key company metrics

  • Open(U.S.) $15.45
  • Previous close(U.S.) $15.62
  • High(U.S.) $15.96
  • Low(U.S.) $15.44
  • Bid / Ask-- / --
  • YTD % change+38.24%
  • Volume1,913,114
  • Average volume (10-day)1,059,867
  • Average volume (1-month)1,414,115
  • Average volume (3-month)1,312,282
  • 52-week range(U.S.) $10.10 to (U.S.) $17.53
  • Beta1.47
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.51
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-26.33%

Nektar Therapeutics has a net profit margin of -26.33%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue133292031
Total other revenue--------
Total revenue133292031
Gross profit124231222
Total cost of revenue9589
Total operating expense53515667
Selling / general / administrative9101010
Research & development34373848
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)------0
Other operating expenses, total--------
Operating income80-23-36-36
Interest income (expense), net non-operating-10-10-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax71-32-46-46
Income after tax71-33-46-48
Income tax, total0002
Net income71-33-46-48
Total adjustments to net income--------
Net income before extra. items71-33-46-48
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items71-33-46-48
Inc. avail. to common incl. extra. items71-33-46-48
Diluted net income71-33-46-48
Dilution adjustment----00
Diluted weighted average shares132127124116
Diluted EPS excluding extraordinary itemsvalue per share0.53-0.26-0.37-0.41
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.53-0.26-0.37-0.41